Alpha 2.0
Login Register
» Authors » Stephen P Creekmore

Stephen P Creekmore

Explore the profile of Stephen P Creekmore including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 10
Citations 780
Followers 0
Related Specialties
Hematology
Oncology
Biomedical Engineering
Top 10 Co-Authors
Thomas A Waldmann
Jason L Yovandich
Thomas A Fleisher
Bonita R Bryant
Carolyn K Goldman
Liyanage P Perera
Mario Roederer
Enrico Lugli
H Clifford Lane
Michael C Sneller
Published In
Blood
J Immunol Methods
Appl Microbiol Biotechnol
Clin Cancer Res
J Clin Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion
Conlon K, Potter E, Pittaluga S, Lee C, Miljkovic M, Fleisher T, et al.
Clin Cancer Res . 2019 May; 25(16):4945-4954. PMID: 31142503
Purpose: The first-in-human clinical trial with human bolus intravenous infusion IL15 (rhIL15) was limited by treatment-associated toxicity. Here, we report toxicity, immunomodulation, and clinical activity of rhIL15 administered as a...
2.
Mammalian cell transient expression, non-affinity purification, and characterization of human recombinant IGFBP7, an IGF-1 targeting therapeutic protein
Jiang M, Yang X, Esposito D, Nelson E, Yuan J, Hopkins R, et al.
Int Immunopharmacol . 2015 Oct; 29(2):476-487. PMID: 26474694
Targeted inhibiting insulin-like growth factor 1 is an effective approach for cancer therapy. Insulin-like growth factor binding protein 7 (IGFBP7) is considered as a potential therapeutic protein. However, producing high...
3.
Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer
Conlon K, Lugli E, Welles H, Rosenberg S, Tito Fojo A, Morris J, et al.
J Clin Oncol . 2014 Nov; 33(1):74-82. PMID: 25403209
Purpose: Interleukin-15 (IL-15) has significant potential in cancer immunotherapy as an activator of antitumor CD8 T and natural killer (NK) cells. The primary objectives of this trial were to determine...
4.
Phase 1 trial of IL-15 trans presentation blockade using humanized Mikβ1 mAb in patients with T-cell large granular lymphocytic leukemia
Waldmann T, Conlon K, Stewart D, Worthy T, Janik J, Fleisher T, et al.
Blood . 2012 Dec; 121(3):476-84. PMID: 23212516
In the present study, Hu-Mikβ1, a humanized mAb directed at the shared IL-2/IL-15Rβ subunit (CD122) was evaluated in patients with T-cell large granular lymphocytic (T-LGL) leukemia. Hu-Mikβ1 blocked the trans...
5.
Purification of clinical-grade disulfide stabilized antibody fragment variable--Pseudomonas exotoxin conjugate (dsFv-PE38) expressed in Escherichia coli
Jiang H, Xie Y, Burnette A, Roach J, Giardina S, Hecht T, et al.
Appl Microbiol Biotechnol . 2012 Aug; 97(2):621-32. PMID: 22890777
Immunotoxins are rationally designed cancer targeting and killing agents. Disulfide stabilized antibody Fv portion-toxin conjugates (dsFv-toxin) are third generation immunotoxins containing only the antibody fragment variable portions and a toxin...
6.
Clinical manufacturing of recombinant human interleukin 15. I. Production cell line development and protein expression in E. coli with stop codon optimization
Vyas V, Esposito D, Sumpter T, Broadt T, Hartley J, Knapp 4th G, et al.
Biotechnol Prog . 2011 Dec; 28(2):497-507. PMID: 22162520
Interleukin 15 (IL-15) has shown remarkable biological properties of promoting NK- and T-cell activation and proliferation, as well as enhancing antitumor immunity of CD8(+) T cells in preclinical models. Here,...
7.
IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood
Sneller M, Kopp W, Engelke K, Yovandich J, Creekmore S, Waldmann T, et al.
Blood . 2011 Nov; 118(26):6845-8. PMID: 22067383
IL-15 promotes activation and maintenance of natural killer (NK) and CD8(+) T effector memory (T(EM)) cells, making it a potential immunotherapeutic agent for the treatment of cancer and immunodeficiency states....
8.
Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques
Waldmann T, Lugli E, Roederer M, Perera L, Smedley J, MacAllister R, et al.
Blood . 2011 Mar; 117(18):4787-95. PMID: 21385847
IL-15 uses the heterotrimeric receptor IL-2/IL-15Rβ and the γ chain shared with IL-2 and the cytokine-specific IL-15Rα. Although IL-15 shares actions with IL-2 that include activation of natural killer (NK)...
9.
Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates
Lugli E, Goldman C, Perera L, Smedley J, Pung R, Yovandich J, et al.
Blood . 2010 Jul; 116(17):3238-48. PMID: 20631381
Interleukin-15 (IL-15) is a cytokine with potential therapeutic application in individuals with cancer or immunodeficiency to promote natural killer (NK)- and T-cell activation and proliferation or in vaccination protocols to...
10.
MTS dye based colorimetric CTLL-2 cell proliferation assay for product release and stability monitoring of interleukin-15: assay qualification, standardization and statistical analysis
Soman G, Yang X, Jiang H, Giardina S, Vyas V, Mitra G, et al.
J Immunol Methods . 2009 Aug; 348(1-2):83-94. PMID: 19646987
A colorimetric cell proliferation assay using soluble tetrazolium salt [(CellTiter 96(R) Aqueous One Solution) cell proliferation reagent, containing the (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) and an electron coupling reagent phenazine ethosulfate], was...